Legend Biotech (LEGN) has released an update.
Legend Biotech’s CARVYKTI® has been shown to significantly improve overall survival in patients with multiple myeloma, reducing the risk of death by 45% compared to standard care in a landmark study. With this advancement, CARVYKTI® is now the first and only cell therapy to demonstrate such benefits as early as the second line of treatment. The treatment has also received FDA and European Commission approval, marking a major step forward in multiple myeloma therapy.
For further insights into LEGN stock, check out TipRanks’ Stock Analysis page.
